

## RESEARCH LICENSE AGREEMENT

This Research License Agreement (the "Agreement") is entered into by and between NCS Pearson, Inc., a Minnesota Corporation, with its corporate and Clinical Assessment offices located at 5601 Green Valley Drive, Bloomington, MN 55437 (NCS Pearson, Inc. and Clinical Assessment shall hereinafter be referred to individually and collectively as "Pearson") and the Children's Hospital of Philadelphia (CHOP) for the Chronic Kidney Disease in Children (CKiD), a Pennsylvania medical and research institution, located at 3535 Market Street CHOP Borth, Suite 870, Philadelphia, PA 19104 ("Licensee").

**WHEREAS**, Pearson is the copyright holder, or has a license from the copyright holder under which Pearson may itself, or license others to, publish, translate and distribute the Test(s) (as defined herein below);

**WHEREAS**, Licensee now wishes to obtain a non-exclusive limited license to adapt the Test(s) and Test(s) Intellectual Property (IP) (as defined herein), copy and incorporate Test(s) items into a paper/pencil test booklet format, along with other assessments, solely for use in the Main Study (as defined herein):

**WHEREAS**, Licensee wishes to administer the Test(s) up to six times to an estimated six hundred (600) research subjects, for an estimated three thousand three hundred (3,300) total Uses of the Test(s), after accounting for attrition, as part of the Main Study;

**WHEREAS**, Licensee wishes to hand score the Test results, or score the Test(s) with Pearson ScoringAssistant<sup>®</sup> software at their Research Sites (as defined herein) and to analyze the results as part of the Main Study;

**AND WHEREAS**, Pearson is willing to grant Licensee a limited, non-exclusive, non-transferable license as described herein below and solely for use in the Main Study of the Research Project (as defined herein) and pursuant to the terms and conditions contained in this Agreement,

**NOW THEREFORE**, in consideration of the premises and the mutual agreements contained herein, the parties agree as follows:

### TERMS AND CONDITIONS

- 1 **Definitions.** For purposes of this Agreement the following definitions will apply:
  - 1.1 "**Contractor**" means any individual or organization other than the Licensee that performs any portion of the Main Study. If Licensee uses Contractors as part of the Main Study of the Research Project, Licensee must obtain, from each Contractor, the Contractor's written agreement to at least the provisions of Sections 5, 6, 7, 8, 9.2, 10, 11, 12, 13, 14, and 15 of this Agreement.

- 1.2 “Intellectual Property Rights (IP)” means all intellectual property rights and interests including, without limitation: (i) all copyrights and copyrightable subject matter, including any and all worldwide applications, registrations, renewals and extensions thereof and all rights of reproduction and publication, rights to create derivative works and all of the rights incident to copyright ownership; (ii) all trade secrets and confidential information, all technology, ideas, know-how and proprietary processes and formulae; (iii) all inventions, designs, models, mask works, patents and pending patent applications; (iv) all trademarks and pending trademark applications applicable to the Test(s); and (v) all causes of action heretofore and hereafter accrued in favor of the owner of such intellectual property rights for infringement of any one or all of the aforesaid intellectual property rights. For clarification, IP Rights do not include any rights relating to any participant data (participant responses) collected by Licensee as part of the Main Study.
- 1.3 “Main Study” means the study involving the administration and Use of the Test(s) for the Research Project.
- 1.4 “Research Project” means the study titled “Chronic Kidney Disease in Children (CKiD) Longitudinal Study”, a longitudinal, multi-institutional observational study of children and adolescents with mild to moderate kidney disease to examine the disease progression, growth, cardiovascular, and neurocognitive functioning of this population and how they change over time, which has an expected duration of approximately six (6) years, involves an estimated 3,300 total Uses the Test(s) and is limited to Licensee’s above address and the research sites listed at Exhibit A, incorporated into this agreement by reference..
- 1.5 “Research Sites” means Licensee’s above address and the research sites listed at Exhibit A.
- 1.6 “Scoring Site(s)” means Licensee’s above address and the Research Sites listed at Exhibit A.
- 1.7 “Test(s)” means the:
- 1.7.1 Fifty-three Manual pages from the *Delis-Kaplan Executive Function System (D-KEFS<sup>TM</sup>)* a comprehensive assessment of the key components of executive function.
- 1.7.2 The Digit Span and Spatial Span subtests and 38 Manual pages from the *Wechsler Intelligence Scale for Children<sup>®</sup>, Fourth Edition Integrated (WISC<sup>®</sup>-IV Integrated)*, a comprehensive measure of learning strengths and difficulties that includes 16 optional subtests.
- 1.7.3 The Digit Span subtest from the *Wechsler Adult Intelligence Scale<sup>®</sup>, Fourth Edition (WAIS<sup>®</sup>-IV)*, an assessment of adult’s overall cognitive ability and four specific domains of intelligence.
- 1.7.4 The Spatial span subtest and 38 Manual pages from the *Wechsler Memory Scale<sup>®</sup>, Third Edition (WMS<sup>®</sup>-III)*, a comprehensive and reliable assessment of adult memory abilities.
- 1.8 “Test(s) IP” means Test items, scales, raw scoring tables, algorithms, or instructions; normative data; item weights; profiles; standard-score conversion tables; reference-sample norming tables; reporting formats; and related materials created, prepared, devised, and combined for the administration, scoring, reporting, and analysis of the Test(s), together with all revisions and derivative works of the Test(s), and includes words, numbers, letters, or other verbal or numerical symbols of indicia and the combinations and compilations of the foregoing, used to express or represent concepts, relationships, facts or other information in any language format or medium now or hereafter known or developed.

1.9 “Use of the Test(s)” means a single administration of each of the Test(s) to a single research subject and the scoring of the result as a part of the Research Project’s Main Study.

2 Term of License. Licensee’s limited license granted hereunder will begin on the date this Agreement is signed by Pearson and will expire on July 31, 2018. Licensee agrees, without qualification of any kind, to cease all activities covered by this License upon the expiration or termination of this Agreement. This Agreement shall not automatically renew without written agreement executed by both parties. Pearson agrees to not unreasonably withhold renewal of this agreement upon request of Licensee.

3 License.

3.1 Grant of License. Subject to all terms and conditions of this Agreement, Pearson hereby grants to Licensee a limited, non-exclusive, non-transferable license, for Licensee’s sole use in the Main Study of Licensee’s Research Project (“License”). The License permits Licensee to:

3.1.1 Reproduce the Test(s) instructions and items, described in Section 1.7 above in the exact order and form in paper/pencil test booklet format, along with other assessments, solely for use in the Main Study;

3.1.2 Reproduce pages 55-73, 79-88, 91-101, 242-245, 258-260, 268-271, and 278-281 of the D-KEFS Examiner’s Manual; pages 269-273 and 370-402 of the WISC-IV Integrated Examiner’s Manual; and pages 269-273 and 370-402 of the WMS-III Examiners Manual thirty (30) times and distribute the copies to selected Research Sites.

3.1.3 Reproduce the answer sheets containing the Test(s) instructions and items for an estimated 3,300 total Uses of the Test(s) as part of the Main Study;

3.1.4 Administer the Test(s) up to six times to an estimated 600 research subjects at the Exhibit A Research Sites as part of the Main Study; and

3.1.5 Score the Test(s) at the Scoring Sites using hand scoring and analyze the results.

4 Payment

4.1 As consideration for the License granted herein:

Licensee will pay to Pearson a non-refundable license fee of Nine Thousand Six Hundred Forty-five Dollars and No Cents (US\$9,645.00) for an estimated total of 3,300 Uses of the Test(s). For any Use of the Test(s) in excess of 3,300, or reproduced Manual pages in excess of 30 accumulated copies, Licensee will pay to Pearson an additional license fee as set forth in Section 4.3 herein below.

4.2 Payment. The Nine Thousand Six Hundred Forty-five Dollars and No Cents (US\$9,645.00) due for the non-refundable license fee will be payable within thirty (30) days from the date this Agreement is signed by Pearson.

4.3 Reporting Requirement Within sixty (60) days after the last day of the term of this Agreement or any other termination of this Agreement, Licensee will deliver to Pearson a true and accurate report (“Report”) of the activities and number of Uses of the Test(s) conducted by Licensee pursuant to the License granted under this Agreement so as to show a statement and accounting for each Use of the Test(s), and shall remit a payment for additional license fees for any Use of the Test(s) in excess of 3,300 or Manual page

reproductions in excess of 30 combined copies. The additional license fee for the Uses of the Test(s) in excess of 3,300 will be assessed at the below rates:

Assessment Product	Subtest	Fee each
WISC-IV Integrated	Digit Span	\$1.75
WISC-IV Integrated	Spatial Span	\$1.75
WAIS-IV	Digit Span	\$1.75
WMS-III	Spatial Span	\$1.75
Manual pages	Each page	\$1.00

Such Usage in excess of 3,300 or 30 groups of Manual pages will be accounted for in Licensee's Report to Pearson.

- 4.4 Books and Records. Licensee will maintain books of account and records pertaining to its exercise of the rights granted under this Agreement in accordance with generally accepted accounting principles.
- 4.5 Audit Rights. Pearson will have the right to inspect and audit Licensee's books of accounts and business records and operations relating to Licensee's fulfillment of its obligations and exercise of the License granted under this Agreement, at the sole expense of Pearson. However, if such audit results in a finding by Pearson that Licensee underpaid Pearson by more than 10% or if Pearson conducts an audit due to Licensee's failure to provide the Report, Licensee will bear the cost of the audit and remit any unpaid amounts to Pearson. Pearson may utilize its own staff or independent certified public accountants to conduct such an inspection and audit. Any such inspection and audit will be conducted during normal business hours, at a time reasonably acceptable to Licensee, at the place(s) where such books, records and operations are normally maintained. The provisions of this Section 4.5 will survive for a period of three (3) years after termination of this Agreement.

## 5 Proprietary Rights.

- 5.1 Proprietary Rights with Respect to the Test(s) and Test(s) IP. Licensee acknowledges that Pearson and its licensors claim valuable proprietary rights in the Test(s) and Test(s) IP including copyrights and/or trade secret rights. Licensee agrees that all intellectual property rights in the Test(s) and Test(s) IP will be and remain in Pearson and its licensors. No ownership rights in and to the Test(s) and Test(s) IP are transferred to Licensee under this Agreement.
- 5.2 Proprietary Rights in the Results of the Research Project. Subject to Pearson and/or Pearson's licensors' proprietary rights in and to the Test(s) and Test(s) IP, and subject further to the terms and conditions of this Agreement, Pearson agrees that Licensee will own all intellectual property and proprietary rights in and to the results of the Research Project. Upon completion of the Research Project, Licensee agrees to provide Pearson with a copy of any published results of the Research Project, and hereby grants to Pearson a perpetual, royalty-free, non-exclusive license to use, reproduce, and distribute copies of the Research Project results, to the extent that such results relate to the Test(s) and subject to any third party rights.

- 6 Limitations on Exercise of Proprietary Rights. Licensee agrees to the following limitations in this Section 6 on its exercise of proprietary rights in and to the Test(s) IP, except with the express written authorization of Pearson.
- 6.1 Licensee agrees not to assign, license, or otherwise transfer to another in any way any rights to reproduce, publish, distribute, create derivative works of, or otherwise exercise proprietary rights in and to the Test(s) and Test(s) IP, without the express written agreement of Pearson.
  - 6.2 Licensee agrees not to copy the Test(s) or Test(s) IP or create any derivative works of the Test(s), or Test(s) IP, except as expressly permitted by this Agreement.
  - 6.3 Licensee agrees to cease all exercise of licensed rights in and to the Test(s) and Test(s) IP. (including, but not limited to, all rights of reproduction, publication and distribution) upon any termination or expiration of this Agreement.
  - 6.4 The limitations of this Section will not apply to any materials or intellectual property or any materials created like answer sheets or record forms contained in Licensee's Research Project which are not based on, or derived from the Test(s) materials, items and intellectual property licensed by Pearson hereunder, and do not copy or incorporate any parts of the materials, items and intellectual property licensed by Pearson hereunder.
- 7 Proprietary Notices. Licensee agrees to include the following proprietary, copyright, and trademark notices on the Test(s), Test(s) IP and/or any other document derived from or incorporating any part of the Test(s) or Test(s) IP whether fixed in a written, electronic, or other storage format in Licensee's possession or control:
- 7.1 Trademark Notices: "*Wechsler Intelligence Scale for Children*", "*WISC*", "*Wechsler Adult Intelligence Scale*", "*WAIS*", "*D-KEFS*", "*Wechsler Memory Scale*", and "*WMS*" are trademarks, in the US and/or other countries, of Pearson Education, Inc. or its affiliate(s).
  - 7.2 Copyright Notices:
    - 7.2.1 *Wechsler Intelligence Scale for Children, Fourth Edition Integrated (WISC-IV Integrated)*. Copyright © 2004 NCS Pearson, Inc. Adapted and reproduced with permission. All rights reserved.
    - 7.2.2 *Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV)*. Copyright © 2008 NCS Pearson, Inc. Adapted and reproduced with permission. All rights reserved.
    - 7.2.3 *Delis-Kaplan Executive Function System (D-KEFS)*. Copyright © 2001 NCS Pearson, Inc. Adapted and reproduced with permission. All rights reserved.
    - 7.2.4 *Wechsler Memory Scale, Third Edition (WMS-III)*. Copyright 1997 NCS Pearson, Inc. Adapted and reproduced with permission. All rights reserved.
- 8 Ethical Standards. Licensee shall administer, score, interpret and otherwise use the Test(s) in accordance with the principles of Ethical Standards of Psychologists established by the American Psychological Association or the Canadian equivalent. Licensee further agrees that in exercising the rights under this Agreement it shall maintain the standards of test security, confidentiality and quality required by Licensee's own profession for the content, condition, and accuracy of all individual score reports prepared by Licensee.
- 9 Warranties
- 9.1 Warranty of Pearson. Pearson warrants that it has the right to grant the License specified herein to Licensee and that the Test(s) IP does not infringe on any valid United States Letters Patent, copyrights, trade secrets or other proprietary rights of any third party



enforceable in the United States, provided, however, that this warranty and representation will not apply to infringement resulting from (a) any additions, modifications or revisions made by Licensee; or (b) the combination of the Test(s) IP with other items, systems or materials not supplied by Pearson. Pearson makes no other warranties. EXCEPT AS EXPRESSLY PROVIDED HEREIN, ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, ARISING OUT OF THIS AGREEMENT ARE HEREBY DISCLAIMED.

9.2 Warranty of Licensee. Licensee shall be responsible for the content and quality of any materials produced pursuant to the grant contained in this License (including, without limitation, the Test(s) answer sheets or Test(s) record forms, Test(s) booklets, or other Test(s) administration materials). Licensee warrants that such materials will be prepared in accordance with generally-accepted applicable professional standards, including, specifically, the *Guidelines for Computer-based Testing* (if applicable) published by the Association of Test Publishers and the *Standards for Educational and Psychological Testing* published by the American Psychological Association or the United Kingdom equivalent. Licensee further warrants that any modification of the Test(s) prepared by Licensee as permitted by under this Agreement will not infringe on any valid United States patent, copyright, trade secrets, or any other proprietary rights of any third party enforceable in the United States.

## 10 Indemnification.

10.1 Indemnification Responsibility of Licensee. Licensee will indemnify, defend, and hold Pearson harmless against any and all third party claims and resulting expenses (including attorneys' fees) and damages awarded by a court of competent jurisdiction, where such third party claim results from: (a) Licensee's use of the Test(s) or Test(s) IP; (b) the exercise of the license granted hereunder; (c) any breach of the warranty against infringement made by Licensee under this Agreement; (d) any representation or warranty that Licensee makes as to the quality, reliability, functionality, applicability of the Test(s) or Test(s) IP, except for any representation or warranty expressly authorized by Pearson in writing; or (e) any other breach of Licensee's obligations and responsibilities under this Agreement. Pearson shall notify Licensee promptly of any such claim. Licensee will not be responsible for any claims arising from negligence or willful misconduct on the part of Pearson as it relates to this Agreement.

10.2 Indemnification Responsibility of Pearson. Pearson agrees to indemnify and hold Licensee harmless from any and all third party claims (including attorneys' fees incurred in defense or awarded by a court of competent jurisdiction) arising out of any breach of the warranty against infringement made by Pearson in Section 9.1 of this Agreement.

11 Limitation of Liability. PEARSON WILL NOT BE LIABLE FOR ANY CONSEQUENTIAL, INCIDENTAL OR SPECIAL DAMAGES, OR FOR ANY LOST BUSINESS, LOST PROFITS OR LOST SAVINGS ARISING OUT OF THIS AGREEMENT, EVEN IF ADVISED OF SUCH DAMAGES. EXCEPT FOR THE INDEMNIFICATION RESPONSIBILITIES SET FORTH IN SECTION 10; IN NO EVENT WILL PEARSON'S LIABILITY UNDER THIS AGREEMENT EXCEED THE TOTAL AMOUNT OF LICENSE FEES RECEIVED BY PEARSON PURSUANT TO THIS AGREEMENT. PEARSON SHALL HAVE NO

RESPONSIBILITY FOR THE QUALITY OF THE TEST(S) OR THE RESULTS OBTAINED THROUGH LICENSEE'S USE OF THE TEST(S).

12 Termination.

- 12.1 Termination for Default. Either party will have the right to terminate this Agreement in the event the other party is in material breach of this Agreement and fails to cure such breach within thirty (30) days after receipt of written notice specifying the breach from the party not in breach. Notwithstanding the foregoing, Pearson will have the right to terminate this Agreement immediately upon prior written notice and a ten day right to cure, in the event Licensee is in breach of any portions of Sections 3, 4 or 15.3 of this Agreement. Pearson can terminate this Agreement upon a reasonable determination that the Licensee is in breach.
- 12.2 Termination for Insolvency and Business Dissolution. This Agreement may be terminated by either party upon written notice to the other in the event the other party becomes insolvent or bankrupt, or if any proceedings are instituted by or against it for relief under laws relating to bankruptcy or insolvency, or upon a general assignment by the other party for the benefit of its creditors, or upon the appointment of the receiver or trustee or any of such party's property or assets, or if such party's business is dissolved or if such party ceased to do business.
- 12.3 Termination for Assignment of Rights. This Agreement may be terminated by Pearson in the event that Licensee assigns or transfers to any third party, any rights granted hereunder. In the event that Licensee or the assets of Licensee are acquired by a third party, an assignment of rights will be deemed to have occurred and Pearson may, at its sole discretion, terminate the Agreement.

13 Survival of Rights and Obligations. In the event of any termination of this Agreement, all rights, obligations and duties under this Agreement will terminate, provided, however, that:

- 13.1 Subject to the limitations contained in this Agreement, termination of this Agreement will not constitute any waiver of a party's rights or remedies at law or in equity to redress any breach of this Agreement by the other party.
- 13.2 In addition to any provisions of this Agreement, which by their express terms survive any termination of this Agreement, the following Sections of this Agreement will survive any termination of this Agreement: 4.5, 5, 6, 7, 8, 9.2, 10, 11, 12, 14, and 15.

14 Effect of Termination. In the event of any termination or expiration of this Agreement or the License granted herein, Licensee agrees:

- 14.1 To immediately cease all exercise of any rights granted under this Agreement including Use of the Test(s) and Test(s) IP and destroy all unused copies of the Test(s), and Test(s) IP, including but not limited to answer sheets or record forms.
- 14.2 Upon Pearson's request, to provide Pearson with written certification with respect to Licensee's compliance with the terms of this Section.

15 General.

- 15.1 Relationship of the Parties. The relationship between the parties established by this Agreement is that of independent contractors, and does not involve any community of interest between the parties. Pearson and Licensee will each conduct its respective businesses at its own initiative, responsibility and expense, and will have no authority to

- incur any obligations on behalf of the other. Neither party intends there to be any third party beneficiaries to this Agreement.
- 15.2 Governing Law. This Agreement will be governed by, construed, and interpreted exclusively in accordance with the laws of the State of Minnesota, without reference to its choice of law rules. Copyright, Trademark and Patent issues will be construed exclusively under U.S. Federal law, with the parties expressly consenting to forum in the U.S. 8<sup>th</sup> Circuit.
- 15.3 Assignment. Neither this Agreement nor any right, license or privilege with respect to the intellectual property licensed hereunder may be assigned, conveyed, sublicensed or otherwise transferred by Licensee to a third party, without the express consent of Pearson. Any attempt to do so will be void. Subject to the limitations of this Section, this Agreement will be binding on and will inure to the benefit of, the parties and their respective successors and assigns.
- 15.4 Obligation to Monitor: Licensee has the obligation to monitor its facilities and research sites to ensure that no use of the Test(s), other than that authorized by the Agreement, occurs. Pearson will have the right to make the final determination, in its sole discretion, as to whether Licensee's facilities are engaged in commercial scoring and other unauthorized use.
- 15.5 Paragraph Headings. The paragraph and section headings throughout this Agreement are for reference purposes only and will not be held to explain or aid in the interpretation, construction or meaning of the provisions of this Agreement.
- 15.6 Modifications. Licensee or Contractor shall have no right to make modifications to the Test(s) without the express written authorization of Pearson.
- 15.7 Publications. Licensee is hereby granted permission to reproduce the scale names in any publication of the results of the Research Project. A proper copyright notice in the name of either NCS Pearson, Inc., followed by the words "Reproduced by Permission", shall be included in any copy made.
- 15.8 Severability. In the event any provision of this Agreement is held to be unenforceable by a court of competent jurisdiction, this Agreement will be enforced to the maximum extent possible.
- 15.9 Equitable Relief. In the event either party is in breach of any of provisions of Sections 5, 6, 7 or 15.3 of this Agreement, the other party will be entitled to equitable relief without proving actual damages.
- 15.10 Waiver. No waiver of any provisions of this Agreement by any party will be deemed to be an ongoing waiver of such provision unless the parties otherwise express in writing.
- 15.11 Timeliness of Execution. If this Agreement is not signed by Licensee and returned for countersignature within thirty (30) days from receipt, the terms of this offer will be withdrawn and the Agreement will be void and of no effect.



15.12 Notices. All notices required or permitted under this Agreement will be made in writing and will be deemed to have been duly given, when delivered, to the addresses set forth below:

<u>If to Pearson:</u>	<u>If to Licensee:</u>
Pearson IP Licensing, Clinical Assessment 19500 Bulverde Road San Antonio, TX 78259 <u>Pas.licensing@pearson.com</u>	Susan Furth, MD, PhD Principal Investigator Chronic Kidney Disease in Children (CKiD) Children's Hospital of Philadelphia 3535 Market Street CHOP North, Suite 870 Philadelphia, PA 19104 <u>furths@email.chop.edu</u>

15.13 Entire Agreement. This Agreement contains the entire Agreement between the parties related to the matters set forth herein and supersedes all previous agreements, proposals, negotiations and correspondence between them whether oral or written related to the subject matter of this Agreement. This Agreement will not be modified, varied, waived or otherwise changed without the mutual, written consent of both parties.

IN WITNESS WHEREOF; the parties have agreed and executed this Agreement as of the date the agreement is signed below by Pearson.

**NCS PEARSON, INC.**

**CHILDREN'S HOSPITAL OF PHILADELPHIA**

By:   
Authorized Signature

By:   
Authorized Signature

Name: Michael Flynn

Name: Susan Furth, MD, PhD

Title: President, Clinical Assessment, North America

Title: Principal Investigator, CKiD

Date: 12-14-12

Date: December 11, 2012

**Exhibit A  
CKiD Research Sites**

<b>CHILDREN'S MERCY HOSPITAL SITES, n=25</b>		
<b>#</b>	<b>Name</b>	<b>PRINCIPAL INVESTIGATORS</b>
8	British Columbia Children's Hospital	Colin White, MD, FRCPC, FAAP*
16	Cardinal Glennon Hospital	Ellen Wood, MD*
28	Egleston Children's Hospital, Emory University	Larry Greenbaum, MD*
5	Cincinnati Children's Hospital and Medical Center	Jens Goebel, MD*; Mark Mitsnefes, MD
15	Seattle's Children's Hospital	Joseph Flynn, MD*
9	Children's Hospital of Alabama	Sahar Fathallah, MD
7	Children's Hospital of Boston	Nancy Rodig, MD*; William Harmon, MD
17	Children's Hospital of Winnipeg	Tom Blydt-Hansen, MD*
31	Children's Kidney Specialists – Idaho	Randall Jenkins, MD*
1	Children's Mercy Hospital	Bradley Warady, MD*
18	LeBonheur Children's Medical Center	Colleen Hastings, MD*
2	Medical College of Wisconsin	Cynthia Pan, MD*
13	Oklahoma University Health Science Center	Martin Turman, MD, PhD*
4	Oregon Health and Science University	Amira Al-Uzri, MD*; Randall Jenkins, MD
27	Phoenix Children's Hospital	Bruce Morgenstern, MD*
11	Rainbow Babies & Children's Hospital	Katherine Dell, MD*
10	St. Louis Children's Hospital	S. Paul Hmiel, MD*
6	Stanford University Medical Center	Cynthia Wong, MD*; Steve Alexander, MD
25	UCSF Children's Hospital	Anthony Portale, MD*
20	University of California – Los Angeles	Isidro Salusky, MD; Ora Yadin, MD*
21	University of California – San Diego	Nadine Benador, MD*; Robert Mak, MD, PhD
3	University of New Mexico Children's Hospital	Craig Wong, MD*
22	University of Texas Southwestern Medical Center	Mouin Seikaly, MD*
12	University of Wisconsin	Sharon Bartosh, MD*
32	Vanderbilt University Medical Center	Deborah Jones, MD*

\* Clinical Site Principal Investigator

**Exhibit A**  
**CKiD Research Sites (continued)**

<b>CHILDREN'S HOSPITAL OF PHILADELPHIA SITES, n=28</b>		
<b>#</b>	<b>Name</b>	<b>PRINCIPAL INVESTIGATORS</b>
80	Carolina Medical Center	Susan Massengill, MD*
83	Children's Hospital of Philadelphia	Susan Furth, MD, PhD*
64	Children's Hospital at Montefiore	Frederick Kaskel, MD, PhD*
51	Children Hospital of Michigan	Tej Matoo, MD*
52	Ann & Robert H. Lurie Children's Hospital of Chicago	Craig Langman, MD*
53	Children's National Medical Center	Kanwal Kher, MD*
85	East Carolina University	Guillermo Hidalgo, MD*
84	Hospital for Sick Children (Sick Kids)	Rulan Parekh, MD*; Lisa Robinson, MD
79	DeVos Children's Hospital at Spectrum	Yi Cai, MD*
55	INOVA Fairfax Hospital for Children	Lauren Weintraub, MD*
50	Johns Hopkins Children's Center	Meredith Atkinson, MD*
57	Indiana University, Riley Hospital for Children	Sharon Andreoli, PhD*
67	Maimonides Medical Center	Juan Kupferman, MD*
68	Mount Sinai Medical Center	Jeffery Saland, MD*
54	Nationwide Children's Hospital, Ohio State University	Hiren Patel, MD*
74	Robert Wood Johnson Medical School-UMDNJ	Lynne Weiss, MD*
81	State University of New York Downstate Medical Ctr	Anil Mongia, MD*
70	Texas Children's Hospital	Poyyapakkam Srivaths, MD
75	University of Florida	Richard Neiberger, MD*
82	University of Illinois at Chicago	Eunice John, MD*
65	University of Iowa	Patrick Brophy, MD*
58	University of Maryland	Susan Mendley, MD*
59	University of Michigan, Mott Hospital	Debbie Gipson, MD*
60	University of North Carolina, Chapel Hill	Maria Ferris, MD*
72	University of Rochester Medical Center, Golisano Children's Hospital at Strong	Marc Lande, MD*; George Schwartz, MD
61	University of Texas, Houston	Joshua Samuels, MD*
73	University of Virginia	Victoria Norwood, MD*
63	Maria Fareri Children's Hospital at Westchester Medical Center	Dmitry Samsonov, MD*

\* Clinical Site Principal Investigator